Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock Holdings Boosted by Farther Finance Advisors LLC

Farther Finance Advisors LLC increased its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 125.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,690 shares of the biopharmaceutical company’s stock after acquiring an additional 1,495 shares during the period. Farther Finance Advisors LLC’s holdings in Catalyst Pharmaceuticals were worth $56,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. JPMorgan Chase & Co. raised its holdings in Catalyst Pharmaceuticals by 9.1% during the third quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company’s stock worth $8,116,000 after purchasing an additional 33,888 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Catalyst Pharmaceuticals by 13.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 417,332 shares of the biopharmaceutical company’s stock valued at $8,710,000 after acquiring an additional 50,888 shares during the last quarter. Wellington Management Group LLP bought a new position in shares of Catalyst Pharmaceuticals during the 3rd quarter valued at about $1,185,000. Redhawk Wealth Advisors Inc. bought a new position in shares of Catalyst Pharmaceuticals during the 4th quarter valued at about $1,273,000. Finally, Spire Wealth Management grew its stake in shares of Catalyst Pharmaceuticals by 1,342.9% in the 4th quarter. Spire Wealth Management now owns 14,429 shares of the biopharmaceutical company’s stock worth $301,000 after purchasing an additional 13,429 shares during the last quarter. 79.22% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on CPRX shares. Robert W. Baird increased their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, March 3rd. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 28th. Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. Stephens reiterated an “overweight” rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Finally, HC Wainwright restated a “buy” rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $32.29.

Catalyst Pharmaceuticals Trading Up 4.6 %

Shares of NASDAQ CPRX opened at $24.23 on Friday. Catalyst Pharmaceuticals, Inc. has a 1 year low of $14.47 and a 1 year high of $24.64. The firm’s 50-day moving average is $22.39 and its 200-day moving average is $21.62. The firm has a market capitalization of $2.94 billion, a PE ratio of 20.53, a price-to-earnings-growth ratio of 3.31 and a beta of 0.84.

Insider Activity

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the sale, the insider now owns 68,873 shares of the company’s stock, valued at $1,521,404.57. This trade represents a 39.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Brian Elsbernd sold 62,975 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now directly owns 188,564 shares of the company’s stock, valued at approximately $4,333,200.72. This trade represents a 25.04 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is owned by company insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.